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Abstract
Substantial population exposure to endocrine disrupting chemicals, combined with available
biomarkers and public concern, has resulted in an explosion of human health effects research. At
the same time, remarkable shifts in the regulations governing the composition of some consumer
products that contain endocrine disruptors (EDs) has occurred. However, important questions
remain as to the weight of evidence linking EDs to human health end points. In this review, we
critically examine the literature linking ED exposures to child neurodevelopment, focusing in
particular on two model exposures to demonstrate issues related to bioaccumulative [e.g.,
polychlorinated biphenyls (PCBs)] and rapidly metabolized (e.g., phthalates) compounds,
respectively. Issues of study design, confounding, and exposure measurement are considered.
Given widespread exposure to these compounds, the potential public health consequences of even
small effects on human health are substantial. Therefore, advancing our understanding of any
impact calls for careful attention to the principles of causal inference.
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INTRODUCTION
Environmental endocrine disruption of normal child development is a rapidly growing area
of research. This increase in scientific attention is in part because exposure to many of these
chemicals was only recently recognized (15, 14, 88). In addition, technological advances in
exposure measurement have provided human biomonitoring data for chemicals of interest,
documenting widespread exposure internationally and across all age ranges (11). The
scientific basis for concern has been amplified by the public outcry about the perceived
influences of endocrine disruptors (EDs) on human health and disease. As a result,
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remarkable shifts in regulations governing the composition of some consumer products have
occurred both domestically and internationally, as has the voluntary removal of certain
chemicals from other consumer products (10, 16, 23). Precautionary regulations may indeed
be warranted, but carefully conducted observational studies may help guide future
regulatory actions while defending against pressure to weaken the current protections.
By definition, the biological mechanism of EDs implies mediation by hormonal
intermediates, not genotoxicity (Table 1), so association sizes are expected to be weak to
moderate in observational studies. Therefore, large sample sizes and appropriate biological
matrices for exposure measurement are a minimum study requirement. To the detriment of
scientific inquiry, however, the single-minded pursuit of resources with these qualities has
resulted in a comparative neglect of attention to principles of study design and inference.
This trend has the potential either to result in the false dismissal of true associations or to
direct inappropriate attention at associations that are not causal.
APPLYING TOOLS OF CAUSAL INFERENCE
Research on EDs and children's health can benefit from careful consideration of causal
inference guidelines tailored to fit diffuse exposures that likely act through biological
intermediates on phenotypically diverse health end points. These circumstances may result
in departures from guidelines for the classic infectious and genotoxic exposures considered
by Hill (30) (Table 1). Endocrine disrupting chemicals have different biological properties,
and health end points may involve a spectrum of severity or exist as a constellation of
symptoms. In addition, disease end points may result from exposure during narrow windows
of development. The wisdom of Hill still resonates despite these differences, but the nature
of ED exposure calls for our attention to be focused on different aspects of study design and
exposure measurement.
Guidelines and Rationale of A.B. Hill (1965) in His Order of Importance and
Reconsiderations for Endocrine Disruptor Research
Strength of association—Hill suggested that stronger associations are more likely to
have a causal basis, largely owing to his belief that unmeasured confounding may be less
likely to completely erase or explain a strong association than a weak association. The
problems of relying on association magnitude as a surrogate for causality have been
described (62); many counterexamples of weak causal associations and strong noncausal
associations exist. In addition, ED associations are expected to be relatively small because
EDs act through hormonal intermediates. Many physiological processes can influence this
mechanism and, likewise, can influence many outcomes.
That being said, uncontrolled confounding is a major threat to validity in ED research, and
the potential sources of it are diverse. A core assumption of causal inference in the context
of observational studies is that of exchangeability: exposed and unexposed individuals are
exchangeable on all factors apart from the exposure of interest (29). However, any factor
that has the potential to be a common antecedent of ED exposure or the childhood health
outcome of interest should be measured and evaluated as a confounder (Figure 1). This
implicates a huge array of factors, including race, socioeconomic factors such as maternal
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education, home environment, diet, breastfeeding, and the sex of the child. Some
problematic confounders include noncontaminant dietary constituents (e.g., omega-3 fatty
acid intake, total calorie intake) that have independent causal associations, positive or
negative, with important child health outcomes (e.g., neurodevelopment, childhood obesity).
Yet, such factors also serve as general markers of exposure to certain ED compounds that
are principally encountered through dietary intake. In this case, classical analytical
approaches to dealing with confounders may be inadequate.
Replication and consistency in findings—Hill was ambivalent about how much
importance to place on replication given that the lack of replication does not refute causality,
nor does its presence definitively confirm it. The effects of some causal agents cannot occur
unless all the necessary component causes are present (62). Indeed, in ED research, various
unknown or unmeasured susceptibility factors may be differentially distributed across
populations. These susceptibility factors have yet to be defined, but they almost certainly
exist. In addition, a lack of replication may result from differences in how confounding was
addressed across studies, or it may occur because a study simply lacked the power to
observe any association. Carefully considering issues of power, residual confounding, and
interaction may help clarify differences in observed associations across studies and point to
future research needs. Still, a body of consistent evidence is essential to making causal
inferences.
Specificity—Hill argues that an exposure linked to a specific site and type of disease that
is not linked to any other mode of disease strongly supports a causal connection between
those two factors. However, he also acknowledges that diseases may have more than one
cause and that some exposures may indeed target multiple end points. ED action is theorized
to work through hormonal intermediates, suggesting that multiple outcomes can be affected
by disrupted hormonal pathways and therefore can also be associated with exposure. Thus, it
is unlikely that associations will be restricted to a single disease end point. For example,
thyroid antagonism is implicated in obesity, puberty and neurodevelopment. Additional
considerations are raised in the Biological Plausibility section below.
Temporality—Exposure must clearly precede the onset of the disease for the association to
be causal. Hill cautions in particular against reverse causality (exposure resulting from
disease rather than causing it), which may be particularly difficult to discern in the context
of diseases with long latent/silent periods or in cross-sectional studies. Attention to the
correct temporal ordering of exposure and disease is critical for ED research. ED exposures
may indeed result from the symptoms or treatment of the disease in question, leading to the
threat of reverse causality. Incomplete knowledge of an exposure source may obscure
opportunities to identify reverse causality.
Prospective designs are the best suited for establishing the link between ED exposure and
childhood health outcomes, including studies that begin in utero and those that begin in
postnatal life. However, in the absence of valid approaches for estimating exposure in the
prenatal period, studies that begin in childhood may suffer from residual confounding by
prenatal exposure if there is some correlation between pre- and postnatal exposure (Figure
1). For persistent exposures that pass from mother to child in utero or during breast-feeding,
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pre- and postnatal exposure biomarkers are almost certain to be highly correlated. In
contrast, rapidly metabolized exposures arising from consumer product use may be less
correlated over these periods. If the ED exposure levels are not highly correlated over the
prenatal and postnatal exposure windows, postnatal exposure-outcome relations may suffer
from less residual confounding due to unmeasured prenatal exposure, but other unmeasured
common causes may still be problematic. In all cases, sensitivity analyses can be conducted
to examine the implications of unmeasured confounding on the observed association (48).
Prospective studies that begin in utero have the advantage of temporal validity for assessing
the causal association(s) of EDs with child health outcomes, but they are impractical for rare
diseases or those with longer latent periods. Cross-sectional or case-control studies are often
used to study the latter scenarios, but these designs have many limitations with respect to
ED research. Cross-sectional studies cannot determine the temporal ordering of exposure
and outcome, so there is an ever-present risk of reverse causality. In addition, a limitation of
both study designs is that many outcomes of interest to child health researchers might in fact
alter childhood exposure to ED compounds (e.g., obesity and/or metabolic syndrome,
abnormal behavioral development). Moreover, many ED exposures are short-lived, in the
range of hours to days, rendering it impossible for biomarker-based measures to represent
temporally antecedent exposures in these study designs. Although National Health and
Nutrition Examination Survey (NHANES) biomonitoring data have been an essential tool
for researchers in establishing the prevalence and population correlates of exposure to many
chemicals in the United States, it is uncertain whether analyses linking concurrent exposure
to existing health complaints in such cross-sectional surveys are justified in light of their
significant limitations.
Case-control studies, with the exception of those nested within prospective longitudinal
cohorts, generally lack banked biological media with which to measure historical exposure
during etiological windows of interest. Although biological measures obtained near the time
of diagnosis are sometimes used as surrogates for exposures that persist in the body for
longer periods [e.g., polychlorinated biphenyls (PCBs); Table 2], these measures may
imperfectly estimate exposure during the etiological period of interest and may suffer from
all the limitations of cross-sectional designs, including temporal ambiguity.
Biological gradient and dose response—Hill (30) gave greater weight to associations
that were stronger at higher levels of exposure, specifically commenting on the persuasive
evidence of a monotonic dose-response curve. He notes that causal evidence “would be
weakened, though not necessarily destroyed, if it depended upon, say, a much heavier death
rate in light smokers and a lower rate in heavier smokers” (p. 295). ED research has charted
its own course with respect to the expected shape of the dose-response function. Low-dose
and non-monotonic dose-response curves are supported by some biological evidence (80).
Observational studies, however, should also recognize that biases may create irregular dose-
response curves (62), such as apparent inverted U-shaped gradients, that result in the false
suggestion of nonmonotonicity. Moreover, monotonicity does not necessarily mean the
results are causal (if, for example, the confounding factor is also linearly associated with
exposure). Therefore, a carefully considered a priori hypothesis about the expected shape of
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the dose-response curve, along with an examination of alternative, noncausal explanations
for the reported dose-response function, is warranted.
Attention to dose response requires a deep understanding of exposure source and
measurement. Although exposure to EDs in the United States is widespread, consumers are
generally unaware of their exposure to these compounds. EDs that are incorporated into
product packaging materials may migrate into the product. Other additives are exempted
from public disclosure on product labels if they are considered trade secrets (e.g.,
proprietary fragrance formulations, patented delivery mechanisms for pharmaceuticals, or
inactive ingredients) (39). This lack of transparency regarding exposure sources means that
using questionnaire-based exposure ascertainment or exposure reconstruction to characterize
an individual's total exposure profile is not currently feasible. As a result, biomarker-based
exposure estimates are the current gold standard because they represent, in principle, an
integrated metric of exposure from all sources, although their limitations are sometimes
underappreciated. This generally limits research on EDs to those studies for which
biospecimens are available. Moreover, many longitudinal cohort studies are not suited to the
study of some EDs because they lack banked urine, which is the preferred analytic matrix
for many rapidly metabolized ED contaminants. A principal concern is that poor exposure
assessment leads to misclassification, which would influence a dose-response curve and, in
extreme cases, invalidate associations. We present a discussion of different choices for
exposure measurement and issues related to quantification, confounding, and cofactors (see
sidebar, Criteria for Exposure Biomarker Measurement in Endocrine Disruptor Research).
Exposure biomarkers: Although individual-level biomarkers are invaluable and have
become the sine qua non for many agents, their numerous pitfalls are often overlooked (see
sidebar, Environmental Mixtures and Biomarkers). For example, twenty-first century EDs,
such as bisphenol A (BPA) and phthalates, are rapidly metabolized, meaning that these
exposure biomarkers reflect only relatively recent exposure (Table 2). Exposure to these
compounds fluctuates over time, suggesting the need for repeated measures. Still, some
urinary metabolites [e.g., monobutyl phthalate (MBP) and certain environmental phenols
apart from BPA] appear to exhibit fairly good intraindividual reproducibility over 6-to-12
months, possibly owing to common patterns of product usage. Conversely, EDs with longer
half-lives [e.g., PCBs, dioxins, polybrominated diphenyl ethers (PBDEs)] now exist at
relatively low concentrations in the environment and are generally measured in blood
samples. It is imperative to choose the correct biological matrix for sampling (Table 2; see
sidebar, Unrecognized Misuse of Phthalate Biomarkers). Issues such as pharmacokinetics
and possible biospecimen contamination are not adequately considered. There is also
considerable interest in using blood products as a matrix for measuring biomarkers of
rapidly metabolized compounds. However, the studies published to date reveal considerable
opportunity for contamination by environmental sources of exposure and have produced
exposure estimates that are orders of magnitude above any estimated ED chemical intake
(Table 2; see sidebar, Unrecognized Misuse of Phthalate Biomarkers).
Most laboratories measure only selected agents (for example, NHANES data report one
major sunscreen ingredient, whereas many products contain up to five). Although
technology has achieved exceedingly low detection limits, in some circumstances, these
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advances may extend to a range in which it is unlikely that exposure would have biological
effects.
Exposure reconstruction: Classic exposure reconstruction has been a cornerstone of
environmental epidemiology, but much of it was based on unique high-level exposures that
could be historically characterized, particularly in the workplace. Accurate reconstruction is
difficult for exposures from multiple and unknown sources. However, if such approaches
could be developed and validated, reconstruction could be more economical and could
provide more accurate information across a window of susceptibility. For example, both
2,3,7,8-tetrachlorodibenzodioxin (TCDD) and PCB exposure biomarkers have been used to
validate job history or fish consumption as markers of exposure, which has allowed cost-
effective retrospective research on large populations. Preliminary research attempting to
quantify exposures to phthalates using questionnaires or job exposure matrices has not yet
succeeded in supplanting biomarker-based ED exposure estimates, although in theory, the
sources and patterns of exposure should permit such a partial exposure reconstruction
strategy.
Environmental monitoring: Although environmental monitoring is more expensive than
reconstruction, it can be more affordable than biomonitoring and has some advantages. Air
or dust measurements can provide a basis for exposure ranking, but, like biomonitoring,
these techniques may be costly if they require special training and equipment. Although
ambient measurements would have the limitation of assuming single exposure sources, as
discussed above, investigators have used this approach successfully to estimate individual-
level exposures to pesticides, polycyclic aromatic hydro-carbons (PAHs), and phthalates.
Biological plausibility—Hill notes that finding a biological basis that can explain the
association under study is helpful. However, he also notes that such information is
inherently limited to what is currently known, which is incomplete. A biological basis is
inherent in (and indeed eponymous with) ED research. By definition, EDs act primarily
through a neuroendocrine pathway upon an end point that is intermediate to classic health
outcomes or disease. Therefore, the mechanistic basis of ED research is a primary and
essential element of causal inference in this field.
In studies of the impact of EDs on child development, biological plausibility, and its
corollary, temporality, are best embodied in longitudinal cohort study designs that begin in
the prenatal period. Brain development proceeds on a trajectory from early pregnancy to the
postpartum period and into early childhood (Table 3). Both experimental and epidemiologic
evidence support the embryonic and fetal periods as windows of vulnerability for insults to
brain development. However, both in utero and childhood exposure to toxicants such as lead
and PCBs have been shown to have a strong influence on child development, although the
relative contribution may vary depending on relative toxicity and window of action. That
being said, prenatal and postnatal exposures are often correlated, and exposure in each
period may independently influence the outcome of interest. Therefore, the most informative
postnatal association likely requires conditioning on a prenatal exposure level, i.e., prenatal
exposure is clearly a confounder of postnatal exposure. However, the reverse is only
possible insofar as postnatal exposure is on a confounding pathway through both known and
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potentially unmeasured common causes (Figure 1). Very few studies in the ED literature
have conducted this type of analysis.
Coherence and analogy—In Hill's paper, coherence and analogy are interrelated
concepts. Ideally, new mechanisms explaining the association between an exposure and a
disease would cohere with what is currently known and shed light on related exposures. In
the case of EDs, these factors become closely related to biological plausibility. For example,
it might be suspected that chemical homologs would act similarly. Carefully considering the
impact(s) of important effect measure modifiers related to a biological pathway may also
help establish coherence with the existing literature.
Experimental evidence—Hill described scenarios that might provide experimental or
quasi-experimental evidence of a causal relation. For example, a scenario in which the
frequency of disease changes if some preventive measure is implemented and the exposure
is removed would constitute powerful evidence. As Hill (30) points out, “our object is
usually to take action” (p. 300). Exposure intervention or reduction may occur by design
(e.g., policy-level interventions) or by nature. However, population-level interventions for
ED exposures may be almost impossible. Because there are multiple related ED exposures
that may impact children's health, health improvement following the elimination or
reduction of a single agent may not be realistic.
CASE STUDIES OF ENDOCRINE DISRUPTOR RESEARCH IN LIGHT OF
CAUSAL INFERENCE GUIDELINES
To illustrate how these causal guidelines can be used to evaluate the evidence linking ED
chemical exposure and child health end points, we selected two quite different model
exposures, PCBs and phthalates, on the basis of approximately 200 reviews on EDs and
child health that have appeared in the twenty-first century. PCBs, which are persistent and
bioaccumulative, are represented in a large toxicology and epidemiologic literature.
Phthalates are rapidly metabolized compounds of emerging interest with respect to
reproductive function and neurodevelopment. Great diversity exists in the potential child
health outcomes associated with both chemicals, including birth size, reproductive toxicity,
growth, obesity, asthma, metabolic syndrome, and pubertal maturation, each of which has a
unique constellation of predictors. Thus, we focus the remainder of our review on aspects of
neurodevelopment. For each model exposure, we evaluate the evidence using biological
plausibility, temporality, dose response (including exposure source and measurement),
consistency and replication.
PCBs AND NEURODEVELOPMENT
Biological Plausibility of PCB Research
PCBs and related organohalogens were twentieth-century toxins; they are still studied
because of ongoing environmental exposures, albeit at low and declining levels. Regulatory
action in the mid-1970s banned PCB production internationally, which resulted in a
progressive decline in exposure levels.
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However, structurally analogous chemicals such as PBDEs have emerged in recent years
with toxicology and exposure patterns similar to PCBs, thereby extending this area of
investigation (see sidebar, Environmental Mixtures and Biomarkers). Health concerns were
raised in the 1970s because of the long half-life and widespread dissemination of PCB
residues worldwide.
The structural homology of PCBs and related halogenated aromatic compounds with
thyroxine and the estrogenic activity of some PCBs (50) are the basis for their endocrine
activity. Extensive molecular research—more than 13,000 references in PubMed—during
the next three decades supported the neurotoxic potential of PCBs. The results of studies of
similarly persistent chlorinated hydrocarbons with thyroid hormone regulation capabilities
(12), including 1,1-dichloro-2,2 -bis(4-chlorophenyl)ethylene (DDE) and 1,1,1-trichloro-2,2
-bis(4-chlorophenyl)ethane (DDT), have been mixed. However, other agents, such as PBDE,
perfluorinated compounds (PFCs), and polybrominated biphenyls, demonstrate similar
associations with thyroid hormone levels. In 1968, the Yusho (rice oil) incident, in which
ingestion of PCB-contaminated rice oil resulted in dramatic harmful effects on multiple
child health outcomes, occurred in Japan. This disaster, along with early PCB research in
rodents and primates, provides the necessary biological link to neurological impairment.
Temporality in PCB Research
In the 1970s, two birth cohorts were established specifically to examine the neurotoxicity of
population exposures in North Carolina and Michigan, and additional studies followed (see
Table 4). Birth cohorts provide a longitudinal design encompassing a vulnerable window for
neurodevelopment consistent with both biological findings and the temporal rela tionship of
exposure to neurodevelopment. Neurobehavior in relation to prenatal exposure has been
examined in these kinds of studies from birth to late adolescence. Sometimes, childhood
exposure was also measured by analyzing PCBs in breast milk or in the children's blood.
Many other studies followed, resulting in a robust literature including a total of 16 birth
cohorts (most of which had assessments at several ages) (59).
Exposure Source, Measurement, and Dose Response in PCB Research
Diet is the chief source of PCB exposure, mainly due to seafood or, in the Faroes, whale
blubber consumption. Importantly, other substances from those sources, such as mercury,
other organochlorines including DDT, lead, and fatty acids, are coexposures that have also
been measured in some of the birth cohort studies. Exposure reconstruction methods have
been used in neurobehavioral research in which fish intake was validated as a surrogate for
maternal PCB exposure. Recent recognition of indoor air contamination of volatilized PCBs
from construction materials in schools adds another exposure source for consideration (47).
Exposure biomarkers for PCBs are equivalent in three matrices and have a relatively long
half-life in the body compared with the in utero window (Table 2), so there is some
flexibility regarding when and how to measure prenatal exposure. Although serum PCB
concentrations vary somewhat during pregnancy owing to the progressive mobilization of
maternal fat stores and plasma expansion, a single assay is broadly representative of the in
utero window if it is properly normalized for lipids (45). In addition to maternal blood, other
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matrices, including cord blood, breast milk, and placenta, have been useful for PCB
biomarker measures. Childhood PCB levels have been assessed in a few studies to
determine whether they exacerbate existing conditions or are incremental to prenatal
exposure. However, child PCB levels cannot be used as a surrogate for perinatal exposure
because body size changes dramatically during early life, and similarly dramatic and
unpredictable changes in child PCB levels occur due to breastfeeding, weight gain, and
continued dietary exposure (40).
Meaningful dose-response analyses require attention to laboratory issues regarding exposure
assessment. Both inter- and intra-laboratory variability in PCB analysis have been
investigated (see sidebar, Environmental Mixtures and Biomarkers). To provide a basis for
comparing PCB-neurodevelopment asso ciations across studies, Longnecker et al. (46) used
a number of assumptions and laboratory data to compute the median exposures among 10
cohorts. The total PCB concentrations determined in the individual studies were
approximately five times the PCB 153 levels. In this and later studies, the median perinatal
PCB 153 levels were 13–450 μg/kg lipid (nine cohorts). Within each of these cohorts, the
fifth through ninety-fifth percentile ranges were 5- to 10-fold around the median (e.g., for
Canada: median 100 μg/kg lipid, range 30–400). Comparable exposure measures in Yusho
victims (1968) and in victims of a similar accident in Taiwan (Yucheng, in 1979) were more
than 10 times as high.
Among the 16 birth cohorts that have been studied, neurodevelopment has been evaluated
from infancy to childhood using a range of age-appropriate assessment tools, including
cognitive (visual-spatial, IQ, and executive functioning), psychomotor, and neurobehavioral
measures (59). Most studies made assessments at several ages. Outcomes were measured on
a continuous scale, but they could also be categorized at levels that identify children at risk
of clinically significant impairment. Recent reports have included outcomes related to
attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).
Overall, outcomes are rather nonspecific in relation to the theoretical trajectory of
development (Table 3). There are several consistent aspects to the observed dose-response
relations among diverse international studies. The relations between PCBs and adverse
neurodevelopment in later childhood were strongest for motor, cognitive, visual recognition,
and executive function (including ADHD and ASD-like behaviors). Overall, studies of
earlier cohorts with higher exposure levels found associations with prenatal but not postnatal
exposure to PCBs. Cognitive and motor deficits in the range of 1 to 5 standard units per unit
of prenatal exposure are nicely illustrated in the Ribas-Fito et al. (59) review of the birth
cohorts, whereas children who had very high prenatal exposures (Yusho and Yucheng)
exhibited deficits of 4 to 10 and 4 to 20 units (cognitive and motor, respectively). However,
recent studies indicate that childhood exposure may also contribute to impaired
neurodevelopment. Perhaps childhood and prenatal exposures are more similar and lower
now than in the earlier cohorts. Simulated exposures based on pharmacokinetics indicated
that prenatal and postnatal exposure may act on different axes (infant attention and activity,
respectively) (81) (Table 3). High exposure has also been related to clinically relevant test
results (60). Jacobson & Jacobson (34) argued that “functionally significant impairment”
was twice as likely to occur in the most highly exposed Michigan children; this kind of
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impairment was not seen in less exposed populations. Jacobson & Jacobson (34) also noted
that in the earliest two US birth cohorts, associations with PCBs were seen in the highest 3–
5% of the exposure range in NC and the highest 11% in Michigan. Stewart et al. (73)
reported an association with higher-chlorinated PCBs, which are most persistent, but not the
lower chlorinated.
Consistency and Replication in PCB Research
Dose-response models are rarely independent of confounding, which varies in complexity
(Figure 1). Coexposures to xenobiotics are often not measured and may also be linearly
associated with an outcome of interest. For example, PCBs and mercury have similar dietary
origins (29), specifically fish consumption, and some research suggests coexposure to
mercury may explain any PCB associations (72, 76). However, exposure through fish
consumption also results in exposure to nutrients that have beneficial effects on
neurodevelopment, such as omega-3 fatty acids. Although few studies adjust for such
coexposures (and in some circumstances, doing so may not be possible), they can be
presumed to be present with widely varying distributions across populations. Considering
the possible implications of cofactors, particularly unmeasured ones, may be helpful when
contrasting association sizes across studies.
Due to the substantial changes in body volume during pregnancy (see Exposure Source,
Measurement, and Dose Response in PCB Research, above), caution is required in
constructing statistical models because of the strong intercorrelations among maternal
weight gain, lipid levels, age, race/ethnicity, socioeconomic status, and PCB levels, even
across the relatively restricted pregnancy time frame, that may result in residual confounding
(89). An interesting recent investigation uncovered an inverse association of PCBs with IQ
after adjusting a null or slightly positive association for socioeconomic negative suppressors
(75). Thus, confounding may cloud associations with temporally declining levels of PCBs,
in part due to an incomplete appreciation of pharmacokinetics or coexposures.
Prenatal and postnatal PCB exposure levels are correlated and practically collinear if a child
is breastfed, so it may be difficult to separate the effects of prenatal and postnatal exposure.
In early investigations of their independent associations, some studies observed a stronger
association of prenatal PCB exposure than breast milk PCB exposure with
neurodevelopment. Explanations include a specific, sensitive prenatal window of
susceptibility. A more likely explanation, however, is that breastfeeding carries benefits that
can offset xenobiotic toxicity, including nurturing and favorable physiological components.
Various approaches have been undertaken to isolate prenatal and postnatal exposure
windows in breastfed infants, such as including the duration of nursing to calculate a total
exposure through breastfeeding in the analysis, examining bottle-feeding versus
breastfeeding, and examining important multivariable statistical models that account for
many important confounders (including exposure in a prior period) (6, 27, 32, 57, 83). Some
recent studies with lower prenatal PCB exposures do find associations with child exposure.
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Taken together, the structural homology of PCBs and related halogenated aromatic
compounds with thyroxine, the Yusho disaster involving the ingestion of PCB-contaminated
rice oil, which had dramatic harmful effects on multiple child health outcomes; and early
PCB research in rodents and primates provide sufficient biological plausibility for any
association of PCBs with neurodevelopmental impairment. Birth cohorts with both prenatal
and postnatal/breast milk measured PCB exposure were established to evaluate the
association between exposure during vulnerable windows and neurodevelopment. Most
studies of PCB exposure and neurodevelopment have observed associations with one or
more domains, particularly earlier studies with higher exposure levels. Because different
studies employed different neurodevelopmental assessment tools, the outcomes are not
always aligned, which may be due more to study design than to biology. In the current
setting of low and declining levels of PCB exposure, important coexposures to both other
pollutants and beneficial nutrients are important to consider.
PHTHALATES AND NEURODEVELOPMENT
Biological Plausibility of Phthalate Research
Early environmental health research on phtha-late diesters focused on potential
carcinogenicity. Later, phthalates were classified as EDs based on extensive research that
documented phthalate antiandrogenicity in rodents (15). Parallels in the antiandrogenic
action of phthalates were observed in rodents and humans in the compromised development
of male genitalia. Although male androgen insufficiency was emphasized, female
reproductive toxicity was also detected. The possible biological link between phthalates and
brain development relies on the disruption of intermediate hormonal markers, including the
thyroid hormone signaling pathway and/or sex steroid hormones. Concern about widespread
exposure and evidence of reproductive toxicity in animals resulted in regulatory action in the
United States and abroad that aimed to limit exposure to some phthalates in specific product
lines (10, 16, 23). To date, six cohort studies (five with biomarkers) and one cross-sectional
study have investigated phthalate exposure in relation to child behavior, intelligence, and/or
neuropsychiatric conditions (13, 21, 41, 42, 44, 77, 85, 90; Table 4).
Temporality in Phthalate Research
Five of the six cohorts we have listed utilized at least one prenatal urine sample to estimate
exposure to phthalates during pregnancy (21, 42, 77, 85, 90), which effectively established
exposure as a temporal antecedent to the measured neurobehavioral outcome. In contrast,
cross-sectional surveys (13, 41) are unable to establish the temporal ordering of exposure
and outcome, and they fail to address one of the key areas of concern with phthalate
exposure and neuropsychiatric conditions: reverse causality (e.g., urinary phthalate levels
could be elevated due to medical treatment for ADHD or other neurodevelopmental
problems).
Exposure Source, Measurement, and Dose Response in Phthalate Research
Sources of exposure to phthalates are incredibly diverse, the scope of which has only
recently been appreciated. Exposure occurs through the diet, personal care products (such as
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cosmetics, perfumes, lotions, and shampoos), adhesives, detergents, PVC products, and
some pharmaceuticals.
Phthalate exposure measurement generally relies on urinary biomarkers. Many urinary
metabolites are measurable and derived from at least ten diesters (dimethyl-, diethyl-,
dipropyl-, dibutyl-, diethylhexyl-, dioctyl-, dinonyl-, didecyl-, and others). A very wide
range of exposure exists, which varies by phthalate type and differs across studies; measured
exposures may range from <1 to > 1,000 μg/liter for some urinary metabolites. Given such a
wide variety of potential exposure sources, it is necessary to measure many metabolites
(which are polar) in an appropriate aqueous matrix (see sidebar, Unrecognized Misuse of
Phthalate Biomarkers; Table 2). Utilization of the oxidative metabolites of phthalates with
side chains of four carbons or more (dibutyl-, diethylhexyl-, dioctyl-, dinonyl-phthalates)
when measuring exposure reduces the likelihood of exposure misclassification due to
contamination in the exposure metric. The relative levels of different metabolites reflect
their common use and the rapidity of their metabolism. There is also some evidence that
multiple biologically active metabolites may have additive effects (15). Bound (e.g.,
glucuronidated) metabolites are an underutilized group of exposure biomarkers; current
technology requires a second assay to measure the glucuronide, and the additional expense
has generally been warranted only to verify that high analyte levels are not purely a result of
contamination by free monoesters.
Although the extrapolation of exposure back to a preceding period is sometimes possible
with persistent contaminants, it is not possible with rapidly metabolized compounds, such as
phthalates, or with other similar agents such as environmental phenols and phytoestrogens.
A one-time biomarker can represent only a relatively recent period with accuracy. However,
some phthalate metabolites appear to demonstrate reasonable temporal stability over periods
of weeks to months (1, 2, 28, 51, 79) (Table 2), which likely reflects common patterns of
product usage over this same time period. This justifies the use of a single urinary assay if
only one is available when analyzing exposure over a relatively limited time frame (see
sidebar, Unrecognized Misuse of Phthalate Biomarkers).
The wide range of phthalate exposure within populations allows the investigation of dose-
response functions. However, the weak biological activity of these agents requires some
attention to potential nonlinearities. Some studies have examined these possibilities by using
graphical techniques or by categorizing the exposure into micromolar-based quantiles (21,
42, 52, 90). The sizes of the associations between phthalates and neurodevelopment are
similar in magnitude to those observed for PCBs, organophosphates, and low levels of lead.
Confounding is a major concern in studies of phthalate exposure and neurodevelopment.
Phthalate exposure biomarkers are known to vary according to age, sex, body size, and race
(69), and these variations likely reflect the typical usage of common consumer products such
as cosmetics and hair treatments. Reproductive-aged women have higher exposures than
men, and non-Hispanic blacks have higher exposures than Hispanics and whites. These
kinds of demographic features may also correlate with known or suspected risk factors for
neurodevelopmental impairment in children, either through poverty or through other features
of a disrupted home environment that correlate with socioeconomic position. In addition,
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coexposures, including exposures to multiple phthalate metabolites, similar agents such as
phenols, or environmental contaminants with similar population distributions such as PAHs
or tobacco smoke, should be considered. Two studies adjusted for some of these
coexposures in their analyses (85, 90). Dietary sources of exposure present all the same
complications mentioned previously. In addition, the occult presence of phthalates in
medications and dietary supplements poses a unique challenge when estimating phthalate
exposure (39). This can be particularly problematic for cross-sectional studies; however,
prospective studies should also consider the implications of this in their analysis.
Consistency and Replication in Phthalate Research
Neurodevelopment outcomes for which results have been reported thus far include infant
neurobehavioral organization (22, 90), early measures of cognitive and psychomotor
development (42, 85), behavioral development and social responsiveness (21, 52, 77, 85),
neuropsychiatric conditions (ASD and ADHD) (41, 44), and IQ (13). Unlike PCBs, no study
has addressed both prenatal and childhood phthalate exposure. Because of the possibility
that boys and girls will be differentially affected by exposure, several studies have examined
boys and girls separately or have focused on male-like behaviors for similar reasons. As a
cautionary note, although the incidence of some conditions is higher in boys than in girls
(e.g., ADHD and ASD), it has not been established that the mechanism for this difference is
hormonal.
Two studies report poorer psychomotor development with increased prenatal exposure to
MBP, although at widely different ages (42, 85). Some consistency is emerging with respect
to childhood behavioral domains. Associations between prenatal exposure to low-molecular-
weight phthalates [e.g., monoethyl phthalate (MEP), MBP] and maladaptive child behaviors
have been reported in three analyses from two cohorts using standardized instruments,
although the ages at administration were different (4–9 years, 7–9 years, and 3 years,
respectively). Two studies report associations with depressive and/or internalizing
symptoms as well as with domains that strongly correlate with anxiety and aggression (21,
85). In these latter domains, the associations were stronger among boys than among girls in
both studies. Although not all the most notable associations were consistent between these
studies, differences in their findings may be attributable to differences in a parent's
awareness of his/her child's internal emotional state, which tends to vary according to the
age of the child.
Summary of Evidence
Like PCBs, phthalates have been shown to interfere with thyroid hormone regulation, which
forms a biological basis for concern with respect to child neurobehavioral and cognitive
development. Because phthalates are rapidly metabolized, prospective cohort studies with
exposure biomarker measures in the prenatal period are essential for establishing temporally
valid associations between exposure and neurodevelopment, and most studies have utilized
this design. The tremendous diversity in sources of phthalate exposure presents serious
concerns about residual/uncontrolled confounding; key areas of concern include exposure to
copollutants such as tobacco smoke, PAHs, or other environmental contaminants with
similar population distributions. Although some agreement among the early studies of
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phthalates and neurodevelopment is emerging, there have been very few studies overall.
Moreover, two of the key studies are of US-based, urban cohorts (in New York City) that
predominantly represent a low socioeconomic status, minority population with a high risk of
behavioral problems. More studies in other populations are required to advance our
understanding of this evolving area of research.
Emerging Toxicants
Two examples of emerging toxicants complement the issues raised by the exposures we
have already discussed in more detail. PFCs are moderately persistent in the body (Table 2),
and some evidence of their hormonal activity has been found. Their possible associations
with multiple domains (e.g., subfecundity, preeclampsia, thyroid hormone regulation, and
neurodevelopment) point to the dilemma of studying EDs with diffuse and sometimes
overlapping outcomes (24, 56, 71, 84). The exposures are well measured, but the matrix
dilution has not been resolved, although it is known that PFCs attach to albumin in blood.
There are very few human data on any health outcome, including neurobehavioral
development, although populations with high exposure due to industrial contamination are
being followed (26, 71). Future research may be able to sharpen both the exposure
measurement and the windows of susceptibility.
BPA is very rapidly metabolized, but it has exquisitely powerful estrogenic activity, which
secures its biological plausibility as an ED. Yet few compelling epidemiology data link
exposure to human health effects, and the most widely publicized findings have arisen from
cross-sectional studies. BPA biomarker levels are uniformly low (e.g., population medians
of 1 to 3 μg/liter in urine), which may be because spot urine samples fail to capture episodes
of high exposure and are thus unable to accurately rank participants according to their usual,
total, or peak exposure level (7, 8). Some reports reveal large proportions of unbound
urinary metabolites that are likely to have arisen from specimen contamination, reminiscent
of failures in phthalate biomarker measures (see sidebar, Unrecognized Misuse of Phthalate
Biomarkers). More generally, the impact of matrix dilution for analytes at low urinary
concentration is problematic because the limited range of biomarker concentrations may
lead to instability in the exposure estimate, particularly at the extremes of the urine
osmolality distribution. Dubious efforts to measure BPA in blood samples are likely to
overestimate true exposures due to uncontrolled sources of sample contamination, in a
similar manner to phthalates. Recent studies confirm that BPA has a similar physiological
distribution to that of phthalates, i.e., blood concentrations of BPA ~50 times lower than
those in urine have been reported (25, 78) (Table 2). Thus, aside from acute exposure
conditions, blood biomarker levels greater than 1 μg/liter are suspect (25); for example,
according to NHANES data, the 95th percentile of BPA urinary concentration is 16 μg/liter,
which corresponds to a serum level of less than 0.5 μg/liter. This urinary BPA level (16 μg/
liter) is roughly equivalent to the peak urinary level following a high-exposure event, such
as receiving BPA-containing dental sealants (median urinary level approximately 1 h post
treatment of 12 μg/liter) (37, 49). Therefore, although BPA may very well present a hazard
to human health, it is not clear that the current approaches to exposure estimation on the
basis of a single, or even a few, spot urine sample(s) are accurate enough to isolate signal
from noise.
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Sufficient data exist to make a strong case for continued research aimed at investigating the
role of EDs in child health and development. However, future epidemiologic research
should base study designs on a cogent hypothesis with attention to the principles of causal
inference. Cross-sectional studies of ED exposure and prevalent health complaints often do
little to advance our understanding of any causal associations and create a body of literature
that has the potential to distract both researchers and the public from pressing public health
concerns. Prudent attention to the principles of causal inference with attention to issues of
exposure assessment will assist in focusing scientific attention toward associations of public
health importance.
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NHANES: National Health and Nutrition Examination Survey
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CRITERIA FOR EXPOSURE BIOMARKER MEASUREMENT IN ENDOCRINE
DISRUPTOR RESEARCH
To be informative in epidemiologic research, environmental exposure biomarkers should
fit the scientific hypothesis. Choice of biomarkers should address basic criteria
encompassing questions of toxicology, pharmacokinetics, quality assurance, and
confounding. Convenient or technologically feasible biomarkers may not always be
causally informative.
Relevance: A clear mechanism linking hormonal disruption with the outcome of interest
is required.
Prevalence: A sufficient range of concentrations and detectability of the exposure
measure is required.
Reliability: Low intraindividual variability in the exposure metric over a window of
interest (high reproducibility over time) or multiple measures are required. The baseline
measure with regard to the prospective outcome must be taken during the proper window
of action; a concurrent biomarker can be used to represent retrospective exposure only if
it is not confounded by extraneous exposure or pharmacokinetic factors that can be traced
to the putative action point.
Measurement: To avoid misclassification, care must be taken with respect to quality
control during sample collection and laboratory analysis, contamination control, and
measurement technology.
Proper statistics: Data analysis will also consider factors affecting exposure biomarkers
(i.e., confounders, including pharmacokinetics, dilution, and susceptibility factors, and
analytic data, e.g., laboratory batch).
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ENVIRONMENTAL MIXTURES AND BIOMARKERS
PCBs are complex mixtures with more than 60 congeners detected in humans. Cohort
studies have used different summary measures. Most studies report some estimate of total
PCBs (e.g., a sum of 3–50 congeners or a 4-congener sum). In dose-response models,
some studies have examined individual congeners plus a total. Noise may be introduced
when congeners that have different concentration ranges are compared if a lower-
concentration compound is less precise. The Longnecker standardization attempted to
avoid this (46) by using PCB 153, which has a very long half-life and is the most
commonly detected, highest concentration congener in nonoccupational exposures. A
disadvantage of using a single PCB proxy is that the resulting associations may suffer
from lack of specificity because PCB 153 is not a surrogate for all types of PCBs (e.g.,
coplanar). PCB subgroups with different biological activities also differ in exposure
level. Thus PCB 153 and other noncoplanar PCBs generally have much higher
concentrations than the dioxin-like coplanar PCBs and short-lived hormonally active
congeners. This can lead to erroneous dose-response trends because of the greater error
associated with low-concentration PCBs. By definition, the precision near the detection
limit is three times the standard deviation of a measurement. For example, if the detection
limit is 0.09 μg/liter (SD 0.03), then a serum PCB level of 0.1 μg/liter (20 μg/kg lipid) has
an analytic precision of 30%. Acceptable intralaboratory precision at higher exposure
levels is 5–10%.
Engel and Wolff Page 26






















UNRECOGNIZED MISUSE OF PHTHALATE BIOMARKERS
Untransformed di(2-ethylhexyl) phthalate (DEHP) and some phthalate monoesters,
including mono(2-ethylhexyl) phthalate (MEHP), are not appropriate biomarkers for
phthalates because they can easily originate from contamination during sample collection
or analysis. The first step of phthalate diester metabolism involves lipase (an enzyme
commonly found in blood, saliva, or skin), which makes the conversion of DEHP to
MEHP [or dibutyl phthalate (DBP) to MBP] possible following contact with
contaminated materials. For DEHP and other high-molecular-weight phthalate diesters,
the oxidative metabolites are resistant to contamination because they require hepatic
conversion. For lower-molecular-weight phthalates, urine clearance of the monoesters is
quite rapid (15). A few carefully controlled studies are helpful for understanding
contamination issues. In these studies, blood levels of MEHP in the range of 100 to 1,000
μg/liter accompanied urine levels ~ 50 fold higher, far beyond what has been reported in
humans. In one report of unusually elevated exposures (15, table 2.3), the highest median
MEHP level in urine was 400 μg/liter, which corresponds to a predicted serum level of 8
μg/liter. If a huge exposure had happened to occur within the past 5 hours (as seen in
some experiments), the serum level could approach the urine level. However, the serum
level of MEHP would never exceed the urine level by orders of magnitude because
clearance is so rapid. Questionable reports found median serum levels of DEHP and
MEHP that would be equivalent to urinary levels at least six- to sevenfold higher than the
NHANES ninety-fifth percentile for children. These implausible levels likely arose from
contamination during sample collection, processing, and analysis. Thus, any associations
between serum phthalate biomarkers and outcomes (such as puberty, birth weight,
endometriosis, and gynecomastia) likely reflect differences in handling during sample
collection.
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Representative directed acyclic graph linking prenatal and postnatal exposure to a child
health outcome. Direct paths connect prenatal exposure with postnatal exposure and with the
child health outcome. Postnatal exposure has only one direct path to the child health
outcome. Prenatal exposure, postnatal exposure, and the child health outcome all have
common causes, which constitute the constellation of possible confounding factors and
pathways. Included are race, socioeconomic status, maternal education, dietary components,
breastfeeding (for postnatal exposure), sex of the child, and others. Notably, prenatal
exposure will confound the independent association of postnatal exposure with any child
health outcome if prenatal and postnatal exposure are correlated and prenatal exposure
exerts an independent effect on the outcome of interest. Thus, the most informative measure
of postnatal association will be conditioned on prenatal exposure. Prenatal exposure,
however, is impacted by postnatal exposure only insofar as they are connected through
common, and possibly unmeasured, causes—i.e., these exposures are potentially connected
through a confounding pathway.
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Table 1
Endocrine disruptors and children's health in relation to causal inference considerations
Endocrine disruptor exposure effects on
child health and development
Environmental exposures considered by A.B. Hill in the
mid-twentieth century (30)
Mechanism Action through hormonal or epigenetic
intermediate
Genotoxic [tobacco smoke, benzo(a)pyrene], directly
neurotoxic (lead), or infectious (cholera, meningococcus)
Susceptible window of
exposure
In utero or early life Assumed to be any time prior to the latent period
Health end point Spectrum of severity or constellation of
symptoms
Clear dichotomy (cancer, cardiovascular mortality,
infection)
Presumed effect sizes Weak to moderate Strong
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Table 2





c Serum Cord Milk Urine Amniotic fluid Half-life Intracorrelations of
biomarker levels over a
window of ~1 year
PCBs
a 15 × 103 100 25 1,000 – – 7–10 years >0.8
PFCs
b – 100 50 1 0.1 1 4 years >0.8
Lead (Pb)
c 50 × 103 100 whole
blood 0.5
plasma
80 1 1 <0.3 1 month 0.7
Phthalates
d – 2 – 7 100 7 12 hours ~0.3-0.7
References:
a
Polychlorinated biphenyls (PCBs) (15, 67, 68, 87, 89).
b
Perfluorinated compounds (PFCs) (9, 38, 66, 70, 82).
c
Pb (3–5, 43, 68).
d
Phthalates (1, 15, 31, 79).






















Engel and Wolff Page 32
Table 3
Trajectory of neurological development
Developmental process Timing
Neurulation 3–4 prenatal weeks
Neuronal migration 6–24 prenatal weeks
Synaptogenesis Third trimester to adolescence
Postnatal neurogenesis Birth to adulthood
Myelination Third trimester to adulthood
Gyrification (brain folds) Third trimester to adulthood
Structural development of prefrontal cortex Birth to adulthood
Neurotransmitter development of prefrontal cortex In utero to adolescence
Adapted from Nelson (55).
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Table 4
Birth cohorts that have reported neurodevelopmental outcomes in relation to PCBs or phthalates
Location and year of recruitment Estimated median exposure, as ng/g lipid
PCB 153 unless indicated otherwise
a N 
b Reference for at least
one citation
Denmark/Faroe Islands 1994–1995 450 182 46, 72
United States/11 cities 1959–1965 140 1,207 17, 46
Germany/Düsseldorf 1993–1995 140 171 46, 83
Germany/Duisburg 2000–2002 1/3–1/2 lower than 1993 cohort above 86
United States/California 1964–1967 130 399 36, 46
United States/Michigan 1980–1981 120 212 33, 35, 46
Netherlands/2 cities 1990–1992 100 395 46, 57
Netherlands 2001–2002 63 62 63
Canada/Northern Quebec 1995–1998 (Nunavik, Inuiti) 100 175 46, 53
United States/North Carolina 1978–1982 80 912 46, 61
United States/New York 1991–1994 40 216 18, 46
United States/New York Placenta 1.5 μg/g wet wt (~ 0.3 μg/g wt PCB
153)
156 74
United States/Massachusetts 1993–1998 30 542 46, 64, 65
Japan/ Hokkaido 2002–2004 23 134 19, 54
Spain 1997–1999 1.9 μg/L 62 58
United States/New York City 1998–2001 0.8 μg/L sum 4 PCBs 151 20
United States/California 1998–2001 59.8 ng/gL sum (~12 ng/g PCB 153) 285 12
Maternal urinary phthalate metabolites (median or other, μg/L) N
United States/New York 1998–2001 130 high-MW 430 low-MW 295 21, 22, 52
United States/New York City 1999–2006 ~88 DEHP and ~47 DBP metabolite sums 319 85
United States/Ohio 2003–2006 DEHP sum: 86 at 16 weeks’ gestation, 68 at 26 weeks’ gestation
DBP sum: 29 at 16 weeks’ gestation, 25 at 26 weeks gestation
330 90
Korea 2006–2009 ~18 sum of 2 DEHP metabolite; MBP 17 460 42
United States/3 cities 1999–2005 23 DEHP and 15 DBP metabolite sums 145 77
Abbreviations: DBP, dibutyl phthalate; DEHP, di(2-ethylhexyl) phthalate; MBP, monobutyl phthalate; MW, molecular weight; PCB,
polychlorinated biphenyl.
a
From Longnecker et al. (46), estimated prepregnancy maternal serum concentration, from two reviews (6, 59) and listed sources.
b
N varies in multiple reports.
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